ACTRN12622000958785尚未招募1 期
Phase 1, Open-label, Two-Cohort Study of Orally Administered PAX-1 in Patients with Moderate COVID-19
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •1. Signed written informed consent by any patient capable of giving consent.
- •2. Aged between 18 and 60 years.
- •3. Patient is currently hospitalized.
- •4. Diagnosis of moderate COVID-19 pneumonia according to WHO criteria (no signs of severe pneumonia [respiratory rate > 30 breaths/min on room air; severe respiratory distress; or SpO2 less than or equal to 93% on room air] and no need for supplemental oxygen) including a positive RT-PCR test for SARS-CoV-2 and lung involvement confirmed with lung imaging technique.
- •5. Able to take oral medication.
- •6. Able to comply with the study protocol.
- •7. Female patients must agree to use a highly effective method of contraception throughout the study and for up to 90 days after stopping treatment.
- •8. Male subjects should use a condom during treatment and for 90 days following the end of treatment. For a non-pregnant WOCBP partner, contraception recommendations should also be considered as described above.
排除标准
- •1. Patients with ECG evidence of a QTcF > 450 ms in men and > 470 ms in women and patients with any other risk factors for torsade de pointes (TdP) (low left ventricular ejection fraction, left ventricular hypertrophy, ischemia, slow heart rate, and electrolyte abnormalities including hypokalaemia and hypomagnesemia).
- •2. Patients with uncontrolled cardiac disease.
- •3. Patients under treatment with drugs having a known risk of prolonging the QT interval and/or inducing TdP.*
- •4. Patients in treatment with drugs having a known risk of causing neutropenia.*
- •5. Patients with known or suspected hypersensitivity to sodium metaarsenite, related compounds or any of the excipients of PAX-1.
- •6. Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
- •7. Patients requiring supplemental oxygen at screening.
- •8. Patient in ICU at screening.
- •9. Immunosuppressive or immunomodulatory drugs (except for corticosteroids) within the past 3 months.
- •10. ALT or AST > 5 x ULN at screening.
- •11. ANC < 1000/µL at screening.
- •12. Platelet count < 50,000/ µL at screening.
- •13. Serum creatinine > 2 mg/dL (> 176.8 µmol/L) or estimated creatinine clearance < 30 ml/min measured or calculated by Cockroft Gault equation.
- •14. Pregnant or breastfeeding.
- •15. Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of screening.
- •16. Patients who in the opinion of the treating physician should not participate in this program (ex: severe acute respiratory distress syndrome, septicaemia).
- •* Concomitant treatments with a known risk of causing neutropenia, and/or of prolonging the QT interval and/or inducing TdP are prohibited during the study.
研究者
相似试验
已完成
不适用
A phase I, multicenter, open-label study of oral ABL001 in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic Leukemia (CABL001X2101)chronic myelogenous leukemia/Philadelphia chromosome-positive acute lymphoblastic leukemia10024324leukemiaNL-OMON55523ovartis15
进行中（未招募）
1 期
A Phase 2 clinical trial of orally taken investigational product (called MLN9708) in adult patients with returning and/or not responding Follicular LymphomaMedDRA version: 14.1Level: LLTClassification code 10029478Term: Nodular lymphomaSystem Organ Class: 100000004864Follicular LymphomaEUCTR2013-002302-32-ITMillennium Pharmaceuticals, Inc.58
进行中（未招募）
1 期
A Phase 2 clinical trial of orally taken investigational product (called MLN9708) in adult patients with returning and/or not responding Follicular LymphomaFollicular LymphomaMedDRA version: 17.0 Level: LLT Classification code 10029478 Term: Nodular lymphoma System Organ Class: 100000004864EUCTR2013-002302-32-GBMillennium Pharmaceuticals, Inc.29
进行中（未招募）
1 期
A Phase 2 clinical trial of orally taken investigational product (called MLN9708) in adult patients with returning and/or not responding Follicular LymphomaFollicular LymphomaMedDRA version: 19.0Level: LLTClassification code 10029478Term: Nodular lymphomaSystem Organ Class: 100000004864EUCTR2013-002302-32-ESMillennium Pharmaceuticals, Inc.58
进行中（未招募）
1 期
A Phase 2 clinical trial of orally taken investigational product (called MLN9708) in adult patients with returning and/or not responding Follicular LymphomaFollicular LymphomaEUCTR2013-002302-32-BEMillennium Pharmaceuticals, Inc.58